Stoic Venture Capital

ADHD is outpacing the standard of care today and we think Neurode will be a big part of the solution. In our recent memo, Partner Harikesh Pushpapathan breaks down why we invested in their pre-seed round. If you're interested in Neurode’s current Beta, please get in touch or reach out directly to Polina Nesterova. #adhd #science #startup

Congratulations to portfolio company Lenexa Medical for being accepted into the #ecoDisruptive program run by Bupa. The program aims to support startups tackling three key areas: Inclusive Health, Supporting Disability and Illness Prevention. The winning start-up will receive $400k AU to scale up their sustainable product or service commercially. Learn more 👉 https://lnkd.in/e366SeBa

Great to finally announce our participation in Neurode, an investment we made before their 3.5m US round led by Khosla Ventures and PsyMed Ventures. ADHD writ large is no longer just a childhood problem. It’s a cross-generational epidemic. Neurode are solving for this by developing a novel non-invasive headset which both 'reads and writes' the brain. The aesthetic headbands you see in this pic, are a far cry to the breadbox device that I saw back in 2022 . Where Nathalie and Damian Sofrevski are today is a testament to the velocity of their execution and sheer obsession with the problem Learn more 👇 https://lnkd.in/gwnJFsAQ Will be releasing some notes on why we invested shortly.

Interested in the "state of the union" in Deep Tech? Hear from our Partner Harikesh and CEO of Cicada Innovations, Sally-Ann Williams at NiceTo's Startup Palette Show LIVE, supported by Investment NSW. When: Next Thursday 19th @ 5:30pm Where: Harrison.ai HQ (Register for address) Register: https://lnkd.in/gtUzKcp5 Join us for an exclusive night, hosted by Preethi Mohan. Get your tickets 👇

NEWS We are delighted that we have been awarded a new US$3.13 million contract extension by the United States Department of Defense (DOD) to fund inclusion of younger adults aged 18–45 in the ongoing Phase Ib study of INNA-051 nasal dry powder formulation and drug product optimization activities. The new funding extends the US$8.18 million already committed by the DOD to support the development of INNA-051. The ongoing Phase Ib study in adults over the age of 60 was initiated in Q2 2024. A DOD funded protocol amendment will support inclusion of individuals aged 18-45 with the aim of informing dose selection for subsequent trials. Results from the study are expected in the Q4 2024. ENA Respiratory CEO, Christophe Demaison, PhD said: “This new funding from DoD is further recognition of the potential of INNA-051 to play a significant role in protecting individuals at risk of serious harm from respiratory viral infections, including those with occupational risk. We are grateful to the DoD’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense-JPEO-CBRND and Defense Innovation Unit (DIU) for their continued support.” Read the full release here https://lnkd.in/eYJwGtkE   To keep up to date follow us or for more information visit our website www.enarespiratory.com   #ClinicalTrial #DrugDevelopment #Immunomodulator #RespiratoryDisease

We recently announced our investment into Kinoxis Therapeutics Pty Ltd Therapeutics, a team addressing some of the most intractable problems faced by humanity today: Dementia + Substance use disorder. Our Partner Harikesh breaks it down in our memo below. #science #research #dementia #venturecapital #startups

Hear from Darren Kelly, CEO of portfolio company Certa Therapeutics on the future of kidney disease and how he thinks the landscape will evolve! Learn more below 👇 https://lnkd.in/gJu9Dcfy

Kinoxis Therapeutics Pty Ltd is pleased to announce the successful completion of a Series B round of capital raise. A total of $14.5 million funding has been raised through this round, led by key investors Uniseed, UniSuper, University of Sydney, Stoic Venture Capital, Avicella Capital, as well as a number of sophisticated investors.   The funds raised will be used to support Phase 2 programs for Kinoxis’ lead drug candidate, KNX100, which addresses behavioural and psychological symptoms across multiple indications, including agitation and aggression in dementia and several substance use disorders.   One of the supported programs is CARES-X, a phase 2 clinical study commencing this month. First of its kind in Australia, CARES-X will be conducted across 8 sites with 60 patients, examining the safety, tolerability and efficacy of KNX100 when used as a treatment of agitation in dementia patients.   Agitation and aggression in dementia not only have a profound impact on caregivers, but also are often the driver for the transition to assisted living facilities, resulting in a significant economic burden to the public healthcare system. Commenting on the fundraise and the CARES-X study, Kinoxis CEO Hugh Alsop said:” “This injection of funding comes at an important time. We are targeting a significant unmet treatment need for dementia patients, potentially broadening the options for them to maintain a higher quality of life. This is a new and highly promising area of development for KNX100, and we are grateful to have had the strong support from our major investors.”   Thanks also to Lis Boyce at Piper Alderman and the team at Bio101 for their support through this round.   For more details on the Series B fund raise and the CARES-X study, read the full press release via this link: https://lnkd.in/gw9Htpem #AgitationinDementia #SubstanceUseDisorder #SeriesB #BiotechInvestment

Congratulations to portfolio company Kinoxis Therapeutics Pty Ltd on the successful completion of their Series B funding round! This critical funding will advance Phase 2 programs for Kinoxis’ lead candidate, KNX100. One program in particular, CARES-X, will explore KNX100’s safety, tolerability, and efficacy in treating agitation in dementia patients. We are thrilled to be participating alongside Uniseed, the University of Sydney, UniSuper and Avicella Capital in this round. An outstanding achievement by Hugh Alsop and the entire Kinoxis team! #dementia #clinicaltrials #research #startups

"I ask the questions about whether we are solving a problem that needs solving, or is a nice to have, and what that does to the market size and trajectory. The business mindset means assessing which market has the fastest regulatory pathway and best prospects for reimbursement." In this edition of AOS, we sit down with Stewart Bartlett, CEO of portfolio company Ferronova. Stewart offers his insights into Ferronova's journey so far, benefits and challenges as a non-clinician and what success means to him. Read below 👇 https://lnkd.in/gRrs459D